Arbutus appoints Melissa V. Rewolinski, PhD to its board of directors

Arbutus Biopharma Corp

Melissa V. Rewolinski appointed to board effective July 12, 2023; board expands to seven members.
She joins Compensation Committee; receives $40,000 annual retainer plus $7,500 for committee service.
Granted option for 110,000 common shares vesting over 3 years; exercise price based on July 12 closing price.
Dr. Rewolinski brings 20+ years pharma experience; previously at Intercept, Amira, Pfizer; currently MVR Consulting.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Melissa V. Rewolinski

Director

ABUS · Arbutus Biopharma Corp

Effective: 2023-07-11
Filed: July 12, 2023, 7:59 PM ET

appointed Melissa V. Rewolinski, PhD to the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Melissa V. Rewolinski was appointed as Director at Arbutus Biopharma Corp.

Action: appointed
Role: Director

Exact text from the filing

appointed Melissa V. Rewolinski, PhD to the Board

View on SEC.gov

Arbutus Biopharma Corp filing history →

Source: SEC EDGAR

accession 0001171843-23-004458

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.